Abstract: Objective To evaluate the efficacy and safety of diammonium glycrrhizinate enteric-coated capsules in the treatment of patients with fatty liver diseases. Methods All randomized controlled trials of diammonium glycrrhizinate for the treatment of patients with fatty liver disease published before June 2014 were collected by searching PubMed，OVID，EMBASE，Cochrance Library，Chinese National Knowledge Infrastructure （CNKI）， Wan-fang Database and VIP Database. Statistical analyses were performed with RevMan 5.0 software. Results A total of 5 articles involving 376 patients with fatty liver disease were included. The overall efficacy[Odds Ratio （OR）=2.19，95%CI 1.19~4.06，P=0.01] and remission of clinical syndrome（OR=3.85，95%CI 2.07~7.16，P<0.0001） of patients in treatment group were better than those in the controls；Compared with patients in control group，there were greater improvement of hepatic function indicators and reduction of serum lipid in patients in treatment group； The weighted mean differences（WMDs） for alanine aminotransferase，aspartate aminotransferase，γ-glutamyltranspe-ptidase，serum total cholesterol and，serum triglyceridewere -15.65（95%CI -21～-10.29， P<0.00001），-17.56 （95%CI -25.99~-9.14，P<0.0001），-7.18 （95%CI -11.94~-2.42，P=0.003），-1.01（95%CI -1.84~-0.18，P=0.02） and -0.77（95%CI -0.92~-0.61，P<0.00001），respectively；But there were no significant differences between the two groups in high density lipoprotein （HDL-L） （WMD=-0.01，95%CI -0.16~0.14，P>0.05） and low density lipoprotein （LDL-L）（WMD=0.04，95%CI -0.30~0.38，P>0.05）；Patients in treatment group had better liver morphology improvement than in controls （50% vs. 26.7%） as revealed by B ultrasound（P=0.0007）；However，the incidence of adverse effect in patients in treatment group was slightly higher than that in controls（11.19% vs. 1.44%，P=0.005）. Conclusion Diammonium glycrrhizinate enteric-coated capsules is effective in improving clinical symptom，liver function，serum lipids and liver morphology in patients with fatty liver diseases.

Key words: Fatty liver disease, Diammonium glycrrhizinate enteric-coated capsules, Therapy, Meta-analysis